A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).

Abstract

The MiNa protocol (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone) was given to 20 patients with advanced B-cell chronic lymphocytic leukemia. Complete remission (absence of all clinical and bone marrow evidence of leukemia) was obtained in 35% of cases; partial response (greater than 50% reduction in organ enlargement and decreasement of lymphocyte count to less than 15(9) X 10/l) was observed in 35% of patients. Of 12 patients (60%) previously treated with chlorambucil and corticosteroids, nine responded to treatment. Toxicity was mild and the relapse rate particularly low. It was concluded that the MiNa protocol represents an effective chemotherapy for advanced and/or progressive CLL.

• Authors: F Ferrara, L Del Vecchio, G Mele, V Rametta, F Ronconi, R Montuori
• Journal: Cancer (Cancer) Vol. 64 Issue 4 Pg. 789-92 (Aug 15 1989) ISSN: 0008-543X [Print] United States
• PMID: 2743271 (Publication Type: Journal Article)

Chemical References

• Vincristine
• Cyclophosphamide
• Peptichemio
• Melphalan
• Prednisone

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cyclophosphamide (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, pathology)
• Male
• Melphalan (administration & dosage)
• Middle Aged
• Peptichemio (administration & dosage)
• Prednisone (administration & dosage)
• Remission Induction
• Vincristine (administration & dosage)